SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is trending downward following a significant post-earnings sell-off driven by weak future sales guidance and concerns over the company's turnaround progress in key international markets. The investor community remains sharply divided, with some actively buying the dip as a long-term value play, while others criticize the brand's loss of cultural relevance and competitive positioning against emerging sportswear rivals.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors react to the company's fiscal Q3 earnings report, which highlighted record revenue and international growth, though community sentiment remains polarized over management and the stock's long-term performance. While some participants are betting on an upside reversal tied to broader cannabis sector catalysts and rescheduling prospects, others remain skeptical, citing concerns over dilution and historical share price declines.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors weigh recent capital allocation moves, including a multi-billion dollar stake repurchase in its Irish manufacturing site, against broader market volatility and geopolitical concerns affecting the semiconductor sector. While the community remains divided between long-term bulls highlighting foundry expansion and AI growth and short-term bears skeptical of manufacturing headwinds, active discussion is dominated by the stock's pronounced intraday volatility and its sensitivity to macroeconomic headlines.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz as investors track positive Phase 3 clinical data for its lead skin disease treatment, sonelokimab, while speculating on the potential for a high-premium buyout. The community remains deeply divided, with some retail investors holding for generational wealth based on clinical performance while others warn of price manipulation, short-selling pressure, and the impact of institutional divestments.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors focus on the commercial launch of YARTEMLEA, with the community closely tracking initial patient uptake, formulary approvals at major transplant centers, and the company's timeline for reaching positive cash flow. While the stock has faced downward pressure due to technical factors and broader market volatility, discussions are heavily centered on upcoming Q1 sales updates, the potential for milestone payments from the Novo Nordisk partnership, and imminent EU regulatory milestones.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is currently experiencing intense volatility following a significant earnings miss and lowered guidance, with the stock drawing heavy attention due to its massive short interest and the ongoing debate over whether it is a value play or a potential bankruptcy candidate. The community is sharply divided, with bulls betting on a short squeeze and long-term luxury market recovery, while bears point to persistent housing market headwinds, tariff-related margin compression, and expensive international expansion as signs of long-term deterioration.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is experiencing heightened investor interest following the announcement of a massive multi-year AI cloud infrastructure agreement, which has sparked intense debate over the stock's potential for a significant short squeeze. Community members are actively discussing the company's low float and the strategic impact of this contract, leading to speculation about aggressive price moves while some remain cautious of potential spoofing and market volatility.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor ongoing project developments, including the upcoming pilot plant operations and the status of the Definitive Feasibility Study. Market participants are actively debating the stock's valuation relative to its rare earth assets while navigating volatility driven by broader sector trends and geopolitical developments.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming 10-K filing and earnings report, with community members closely tracking the company's aggressive debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish participants are actively discussing a potential valuation re-rating and the possibility of a short squeeze, while keeping a watchful eye on management's next steps to address previous legal overhangs and restore institutional confidence.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing significant speculative activity as traders draw comparisons to its past parabolic runs, fueled by a combination of tight float, high short interest, and persistent community speculation regarding a potential meme-style short squeeze. While bulls are actively targeting rapid gains and waiting for volume-driven breakouts, a vocal segment of the community remains skeptical, frequently highlighting the company's lack of revenue and warning others about the risks of being left as exit liquidity in a pump-and-dump setup.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 4.4% - Should You Sell?

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Should You Sell...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 0.7% - Here's What Happened

Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 0.7% - Should You Buy...

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 3.1% - Should You Buy?

Tiziana Life Sciences (NASDAQ:TLSA) Trading 3.1% Higher - Still a Buy...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 7.4% - Still a Buy?

Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 7.4% - What's Next...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Here's Why

Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 4.4% - Should You Sell...

Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 4.5% - Here's Why

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.5% - Here's What Happened...

Nasdaq-listed shares of Tiziana Life Sciences (TLSA) rose 2% by Thursday afternoon after the company announced that it will advance its second asset, TZLS-501, and pursue non-dilutive funding strategies for its development.TZLS-501 is a fully human anti-IL-6 receptor monoclonal antibody or a biological therapy that blocks the action of interleukin-6 protein. Tiziana <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-advance-tzls-501-its-fully-human-il-6r-monoclonal">sees</a> potential to develop it as a monotherapy or in combination with its lead candidate, as well as with other anti-inflammatory and anti-infective agents.The company stated that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions where excessive IL-6 signaling plays a central role, such as rheumatoid arthritis (RA), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), systemic lupus erythematosus, and various types of cancer.The company also stated that it will continue to advance intranasal Foralumab as its lead program, not diverting resources or focus from it. The firm is currently evaluating Foralumab in the treatment of multiple sclerosis, a chronic autoimmune disease in which the immune system attacks the protective myelin sheath surrounding nerve cells in the brain and spinal cord, causing numbness, vision problems, muscle weakness, balance issues, and fatigue.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TLSA">TLSA stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:573/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_1_37_07_PM_png_487989b630.webp" alt="TLSA's Sentiment Meter and Message Volume as of 1:37 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="573" height="66"><figcaption>TLSA's Sentiment Meter and Message Volume as of 1:37 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes that the stock has “so much potential.”<stembedurl>https://stocktwits.com/GoCubsGo1124/message/629975723</stembedurl>Tiziana said on Thursday that the <a href="https://stocktwits.com/news-articles/markets/equity/tourmaline-stock-rockets-pre-market-after-novartis-buy-out-announcement/chwKP7BRdt5">recent acquisition</a> of Tourmaline Bio by Novartis for about $1.4 billion validates the importance of IL-6 therapeutics. The acquisition, announced earlier in September, includes Tourmaline’s Pacibekitug, a monoclonal antibody that targets IL-6, which is being evaluated as a treatment option for atherosclerotic cardiovascular disease.“With recent market developments, we feel it is an opportune time to explore TZLS-501’s development,” said Tiziana CEO Ivor Elrifi.TLSA stock nearly tripled in value this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-terminates-study-of-bimagrumab-in-obesity/chDlEmYR34I">Eli Lilly Terminates A Study Of Bimagrumab In Obesity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’

Tiziana said that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions.

Equity

Tiziana said that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions.


AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer’s. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Current Price	$1.25
Prev Close	$1.17
Open	$1.28
Dividend Yield	N/A
50-Day Moving Average	$1.40
Beta	0.76
Avg. Volume	136,345.85
PE Ratio	-10.24

52-Week High	$2.60
52-Week Low	$0.73
Market Capitalization	$139.06M
EPS (Annual)	N/A
Price to Book	15.11
Revenue Per Employee	N/A

TLSA
Tiziana Life Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TLSA News

TLSATiziana Life Sciences Ltd